Clinical Trial 47020

Chicago, IL 60647


Efficacy of zavegepant compared to placebo as a preventive treatment for migraine   (See Ad)

  1. Age of onset of migraines prior to 50 years of age
  2. Migraine attacks, on average, lasting 4 - 72 hours if untreated
  3. Per subject report, 4 - 18 migraine attacks of moderate to severe intensity per month within the last 3 months prior to the Screening Visit
  4. Six or more migraine days during the Observation Period
  5. Not more than 18 headache days during the Observation Period
  6. Ability to distinguish migraine attacks from tension/cluster headaches
  7. Subjects on prophylactic migraine medication are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change during the course of the study.

Qualified Participants May Receive:

Compensation for time and travel

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.